

Amendments to the Claims

1-21. Canceled

22. (Previously presented) A method of inducing pulmonary vasodilation comprising: introducing an aerosolized adenoviral vector comprising a nitric oxide synthase gene operably linked to an expression control element into the lungs of a mammal in need of pulmonary vasodilation; wherein the introduction of said vector into the lungs of said mammal results in pulmonary vasodilation that does not significantly affect systemic blood pressure or cardiac index.

23. (Previously presented) The method of inducing pulmonary vasodilation as claimed in claim 22, wherein said mammal is a human.

24. (Previously present) The method of inducing pulmonary vasodilation as claimed in claim 23, wherein said nitric oxide synthase gene is the endothelial nitric oxide synthase gene.

25. (Previously presented) The method of inducing pulmonary vasodilation as claimed in claim 24, wherein said endothelial nitric oxide synthase gene is transduced into the lungs of said human in a viral vector.

26-27. Canceled

28. (Previously presented) A method of treating pulmonary hypertension comprising: introducing an aerosolized adenoviral vector comprising nitric oxide synthase gene operably linked to an expression control element into the lungs of a mammal in need of treatment for pulmonary hypertension; wherein the introduction of said vector into the lungs of said mammal results in pulmonary vasodilation that does not significantly affect systemic blood pressure or cardiac index.

29. (Previously presented) The method of treating pulmonary hypertension as claimed in claim 28, wherein said mammal is human.

30. (Previously presented) The method of treating pulmonary hypertension as claimed in claim 29, wherein said nitric oxide synthase gene is the endothelial nitric oxide synthase gene.

31. (Previously presented) The method of treating pulmonary hypertension as claimed in claim 30, wherein said pulmonary hypertension is primary pulmonary hypertension.

32. (Previously presented) The method of treating pulmonary hypertension as claimed in claim 30, wherein said pulmonary hypertension is secondary pulmonary hypertension associated with cardiac or pulmonary disease.

33. (Previously presented) The method of treating pulmonary hypertension as claimed in claim 30, wherein said endothelial nitric oxide synthase gene is transduced into the lungs of said human in a viral vector.

34. Canceled

35. (Previously presented) The method of treating pulmonary hypertension as claimed in claim 28 wherein said adenovirus vector is AdCMVceNOS.

36-39. Canceled

40. (Currently amended) A method of inducing pulmonary vasodilation comprising: administering, by aerosol administration, to a mammal in need of pulmonary vasodilation an effective amount of the pharmaceutical composition comprising a nucleic acid encoding a nitric oxide synthase gene operably linked to a pulmonary tissue specific expression control element, an adenoviral vector, a pharmaceutically acceptable carrier vehicle of claim 37; and an effective amount of at least one drug selected from the group consisting of an immunosuppressive agent and a phosphodiesterase inhibitor; wherein inducing said pulmonary vasodilation does not significantly affect systemic blood pressure or cardiac index.

41. (Previously presented) The method of inducing pulmonary vasodilation

as claimed in claim 40, wherein said mammal is human.

42. (Previously presented) The method of treating pulmonary hypertension as claimed in claim 22 wherein said adenovirus vector is AdCMVceNOS.

43. Canceled